Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Jones Lang LaSalle Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Jones Lang LaSalle Inc trades at $362.41 (market cap $16.44B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| BIO | JLL | |
|---|---|---|
Market Cap | $9.39B | $16.44B |
Sector | Health | Real Estate |
52-Week High | $356.25 | $373.24 |
52-Week Low | $241.71 | $280.16 |
Enterprise Value | $9.14B | $19.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
JLL trades at $362.38, down 0.36% on the day, near its 52-week high. The stock shows a bullish technical trend with consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M, and analysts project further growth in 2026. Positive sentiment is driven by strong Q2 2026 results and AI-related real estate demand highlighted in recent company research.
Outlook remains positive with a consensus price target of $391.50, though risks include market volatility and execution challenges in capital markets. The stock offers growth potential from expanding profit margins and strategic positioning in AI-impacted real estate sectors, balanced by economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
